IDEXX Laboratories, Inc. $IDXX Shares Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,040 shares of the company’s stock after purchasing an additional 1,225 shares during the period. Harvest Fund Management Co. Ltd’s holdings in IDEXX Laboratories were worth $6,116,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after purchasing an additional 86,040 shares during the last quarter. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. Geode Capital Management LLC lifted its holdings in IDEXX Laboratories by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after acquiring an additional 86,263 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in IDEXX Laboratories by 14.0% in the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock valued at $843,503,000 after acquiring an additional 161,782 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.7%

IDEXX Laboratories stock opened at $564.74 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The stock’s fifty day simple moving average is $563.32 and its 200-day simple moving average is $632.63. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $44.55 billion, a P/E ratio of 41.59, a P/E/G ratio of 3.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company earned $2.91 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.